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Abstract
In this study, we aimed to evaluate the impact of surgical wait time (SWT) on outcomes of patients with renal cell carcinoma (RCC), and to 
investigate risk factors associated with prolonged SWT. Using the National Cancer Database, we retrospectively reviewed the records of patients 
with pT3 RCC treated with radical or partial nephrectomy between 2004 and 2014. The cohort was divided based on SWT. The primary out-
come was 5-year overall survival (OS). Logistic regression analysis was used to investigate the risk factors associated with delayed surgery. Cox 
proportional hazards models were fitted to assess relations between SWT and 5-year OS after adjusting for confounding factors. A total of 
22,653 patients were included in the analysis. Patients with SWT > 10 weeks had higher occurrence of upstaging. Using logistic regression, we 
found that female patients, African-American or Spanish origin patients, treatment in academic or integrated network cancer center, lack of 
insurance, median household income of <$38,000, and the Charlson–Deyo score of ≥1 were more likely to have prolonged SWT. SWT > 10 
weeks was associated with decreased 5-year OS (hazard ratio [HR], 1.24; 95% confidence interval [CI], 1.15–1.33). This risk was not markedly 
attenuated after adjusting for confounding variables, including age, gender, race, insurance status, Charlson–Deyo score, tumor size, and surgical 
margin status (adjusted HR, 1.13; 95% CI, 1.04–1.24). In conclusion, the vast majority of patients underwent surgery within 10 weeks. There is a 
statistically significant trend of increasing SWT over the study period. SWT > 10 weeks is associated with decreased 5-year OS. 
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Advanced stage renal cell carcinoma (RCC) remains as one 
of the most lethal urological cancers in spite of advance-
ments made in the diagnosis and treatment over the last 
decade (1). In the United States, there are approximately 
74,000 new cases and almost 15,000 deaths from RCC each 
year (2). Partial nephrectomy or radical nephrectomy with 
curative intent is the treatment of choice for RCC. Treatment 
delay, sometimes in months, occurs when there is increase in 
surgeon case load, insurance issues, and preoperative optimi-
zation of medical comorbidities. Globally, the surgery wait 
time (SWT) for cancer treatment has increased over the last 
decade (3) combined with an aging population and retire-
ment of physicians.
From a patient’s perspective, prolonged waiting for cancer 
treatment causes anxiety and distress, but current published 
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medical literature has failed to provide a definitive conclusion 
or insight into change in outcomes resulting from prolonged 
SWT (4, 5). One of the most frequent questions that a sur-
geon or the scheduler encounters in clinic is whether the pro-
longed SWT has a negative impact on oncologic outcomes. It 
has been shown in the case of muscle invasive bladder can-
cer that radical cystectomy delayed for more than 12 weeks 
results in increased risk of disease-specific and all-cause mor-
tality (6). Similarly, prolonged time to surgery confers lower 
overall and disease-specific survival in breast cancer, and a 
shortened delay is associated with benefits comparable to 
some standard therapies (7). 
To date, few reports have investigated the effect of pro-
longed SWT on oncologic outcomes following nephrectomy. 
In this study, we used the National Cancer Database (NCDB) 
to investigate the impact of delayed surgery. We specifically 
examined the pT3 group as this represents advanced stage 
tumor that has invaded locally, and it could be benefited the 
most from timely treatment.
Materials and Methods
Using the NCDB, we retrospectively reviewed the records of 
adult patients (aged ≥18 years) with pT3 RCC treated with 
radical nephrectomy or nephron sparing surgery between 
2004 and 2014. The NCDB is a hospital-based clinical can-
cer registry established in 1989 that collects data from more 
than 1500 hospitals in the United States, capturing more 
than 70% of all newly diagnosed cancers (8, 9). The follow-
ing histology codes were used to select the patients: 8255, 
8260, 8310, 8316, 8317, 8318, and 8319. Patients whose final 
pathology reports presented benign tumors were excluded 
from the study. The SWT in days was derived from “Defin-
itive Surgical  Procedure, Days from Dx.” The diagnosis 
of RCC is based on preoperative cross-sectional imaging. 
A small group of patients had a 0 day interval between diag-
nosis and surgery, and were excluded from the analysis as 
this group likely represented referral from outside hospital 
and such SWT was incorrect. Patients with metastatic dis-
ease were also excluded from the study. 
Follow-up time in months was calculated using last date 
of contact or date of death since definitive surgery. The pri-
mary outcome was 5-year overall survival (OS), which was 
calculated using vital status (alive or death) and last date of 
contact since definitive surgery. We used Cox proportion-
al-hazards model to analyze the effect of SWT in weeks, and 
found a significant difference in the 5-year OS at a time of 10 
weeks. This time was used for subsequent analysis. 
Patient demographics and tumor characteristics were 
summarized and compared between those who had surgery 
within and after 10 weeks. We then performed trend analysis 
of SWT for the study period using the Jonckheere– Terpstra 
test. Binominal logistic regression analysis was used to 
investigate the risk factors associated with SWT > 10 weeks. 
We used Chi-square test to compare perioperative outcomes 
between the two groups, including surgical margin status, 
30-day mortality, 90-day mortality, and readmission within 
30 days of discharge. We used the Mann–Whitney U-test 
to compare the length of stay. Patients whose preoperative 
clinical staging was cT1 or cT2 were captured and marked 
as upstaging. The rate of upstaging was compared in two 
groups. Logistic regression analysis was carried out to inves-
tigate whether SWT > 10 weeks was associated with risk of 
upstaging after adjusting for confounding factor, tumor size. 
Next, Cox proportional hazards models were fitted to assess 
relations between SWT and 5-year OS, adjusting for patient 
demographics (age, gender, race, and insurance status), 
comorbidities, and tumor characteristics (Charlson–Deyo 
score, tumor size, and surgical margin status). 
All statistical analyses were performed using SPSS ver-
sion 25.0 (SPSS, Inc., Chicago, IL). P < 0.05 was considered 
significant.
Results
A total of 22,653 patients from 2004 to 2014 were included in 
the analysis. The median follow-up time was 31 months. The 
median interval between diagnosis and definitive surgery was 
29 days, and 85.3% of the patients underwent nephrectomy 
within 10 weeks of diagnosis. Patient demographics and 
tumor characteristics are summarized in Table 1. 
The Jonckheere–Terpstra test for ordered alternatives 
showed that there was a statistically significant trend of 
increasing SWT over the study period (P < 0.001, Figure 1). 
There was no statistical difference in the length of stay and 
readmission rate between the two groups (Table 2). Patients 
(n = 3340) who had a delay of more than 10 weeks had 
significantly higher occurrence of upstaging (cT1 or cT2 
upstaged to pT3) compared to those who underwent surgery 
within 10 weeks. On logistic regression analysis, SWT within 
10 weeks was associated with less chance of upstaging after 
adjusting for tumor size (adjusted odds ratio [OR], 0.71; 95% 
CI, 0.65–0.78). In all pT3 patients, the 30-day mortality was 
2% (n = 447), while 90-day mortality was 5.3% (n = 1208). 
There was no significant difference in 30-day or 90-day mor-
tality rates between the two groups. Interestingly, patient 
who underwent nephrectomy within 10 weeks had a positive 
surgical margin rate of 16.8%, which was significantly higher 
than that of those with SWT > 10 weeks. No significant dif-
ference was noted in 30-day readmission rate between the 
two groups.
Using logistic regression, we found that female patients, 
African-American or Spanish origin patients, treatment in 
academic or integrated network cancer center, lack of insur-
ance, median household income of less than $38,000, and 
the Charlson–Deyo score of ≥1 were more likely to have a 
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Table 1: Patient demographics and tumor characteristics.


































































































































SWT: surgical wait time.
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Table 2: Treatment outcomes by groups.
P-value SWT < 10 weeks SWT > 10 weeks
























30-Day mortality 0.606 390 (2%) 57 (1.7%)
90-Day mortality 0.659 1051 (9%) 157 (4.7%)
SWT: surgical wait time; LOS: length of stay.
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Figure 1: Trend analysis of surgical wait time (SWT) for the study period 2004–2014. Figure demonstrates the median SWT of 
each year. The Jonckheere–Terpstra test shows a statistically significant trend of increasing SWT from 2004 to 2014.
delay of more than 10 weeks (Table 3). SWT > 10 weeks was 
found to be associated with decreased 5-year OS compared 
with patients who had definitive surgery within 10 weeks 
(hazard ratio [HR], 1.24; 95% CI, 1.15–1.33). This risk 
was not markedly attenuated after adjusting for confound-
ing variables, including age, gender, race, insurance status, 
Charlson–Deyo score, tumor size, and surgical margin status 
(adjusted HR, 1.13; 95% CI, 1.04–1.24; Table 4). 
Discussion
Prolonged SWT has significant impact on the psycholog-
ical wellbeing of cancer patients (4). In the current study, 
we demonstrated that delayed nephrectomy for more than 
10  weeks from the time of diagnosis is associated with 
decreased 5-year OS in a group of pT3 RCC patients within 
a national database. Additionally, we found that female 
patients, African-American or Spanish origin patients, treat-
ment in academic or integrated network cancer center, lack 
of insurance, median household of income less than $38,000, 
and the Charlson–Deyo score of ≥1 are more likely to have a 
delayed definitive surgery.
The current recommendation for treatment of RCC greater 
than 4 cm in size is nephrectomy. This could be performed 
through either open approach or laparoscopic or robotic 
approach. With a wide adoption of da Vinci Surgical Sys-
tem, radical nephrectomy and partial nephrectomy are per-
formed more routinely via robotic or laparoscopic approach 
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Table 3: Logistic regression analysis for surgical wait time 
(SWT) > 10 weeks.






























































































OR: odds ratio; 95% CI: 95% confidence interval.
Table 4: Multivariate cox regression for 5-year overall 
survival.






















































































HR: hazard ratio; SWT: surgical wait time; 95% CI: 95% confidence 
interval.
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in tertiary care centers. Nevertheless, most surgeons who 
perform robotic surgical procedures are assigned block time 
because of the limited number of robotic systems available 
in most hospitals. A recent study has shown that this causes 
a bottleneck effect and increase in the number of patients 
with considerably lengthy waiting time for surgery (10). This 
factor is not included in our study, but it may affect the deci-
sion-making of surgical approach and ultimately SWT.
In 2006, Canadian Surgical Wait Times (SWAT) Initiative 
proposed a recommended maximum wait time of <90 days 
for patients with T1a RCC and <28 days for patients with 
symptomatic tumors (11). However, previous reports have 
shown that small renal masses tend to grow slowly with lin-
ear growth rate of 0.13–0.7 cm/year, and these tumors can 
be safely checked (12, 13). Active surveillance remains a rea-
sonable alternative to surgery for these tumors for elderly or 
comorbid ill patients. For T1a RCC, the interval between 
diagnosis and nephrectomy has been reported to be more 
than 2 years in literature (14, 15). In a group of 82 patients 
with a median tumor size of 2 cm, surgical management 
at 6–97 months has not resulted in limitation of treatment 
options or a high risk of disease progression (16).
Kim et al. reported an analysis on delaying radical 
nephrectomy for stage II or higher RCC (17). SWT of 1–3 
months was not an independent predictor of pathological 
upstaging, recurrence-free survival, or cancer-specific sur-
vival (CSS). On subgroup analysis by TNM staging system 
(cT2NxcM0 and cT3-4NxcM0), SWT of 1–3 months was not 
an independent predictor of pathological upstaging and was 
not associated with poor recurrence-free survival (RFS) or 
CSS. However, patients with SWT > 3 months were excluded 
from the analysis. In a single institution analysis, a group of 
655 patients with 6.4 ± 4.4-cm renal tumors who underwent 
partial or radical nephrectomy were reviewed retrospec-
tively: 64.1% and 94.3% of the patients had surgery within 
30 days and 3 months, respectively. OS and disease-specific 
survival were not affected by surgical wait time regardless of 
how time was analyzed. Interestingly, in univariate analysis, 
5-year recurrence-free survival was poorer in patients under-
going surgery within 1 month, likely secondary to larger, and 
more sinister-appearing renal masses being pushed up in the 
operating schedule (18). Again, this study has not included 
the patients who underwent surgery in more than 3 months. 
In another single institutional analysis, patients with a tumor 
size of 5.5 ± 3.45 cm were included. SWT stage for stage was: 
clinical T1 at 57.12 days, clinical T2 at 36.8 days, and clinical 
T3 and T4 at 30.32 days. There was no statistically signifi-
cant evidence for upstaging or progression during the wait-
ing period (19). Mano et al. found that for patients with renal 
mass of >4 cm, SWT was not associated with disease upstag-
ing, recurrence, or CSS (20). Longer SWT was associated 
with decreased OS. Older age, non-white race, higher BMI, 
higher American Society of Anesthesiologists (ASA) and 
Charlson comorbidity index (CCI) scores, incidental pre-
sentation, smaller tumor size, non-clear cell histology, and 
treatment with partial nephrectomy were significantly asso-
ciated with SWT > 3 months on univariate analysis (20). In 
our study, we found that treatment in academic or integrated 
network cancer center was associated with delayed surgery. 
However, we suspect that this was due to referral patterns 
common with tertiary referral centers because of increasing 
complexity of the case which mandates multidisciplinary 
workup in medical center and potential cardiac evaluation, 
in addition to case load contribution. Indeed, patient having 
the Charlson–Deyo score of 1 or ≥2 and an HR of 1.25 and 
1.63 would have an SWT > 10 weeks in our analysis. This 
delay in surgery reflects the preoperative workup and optimi-
zation of comorbidities that take up time. 
This study has several limitations. First, this is a retro-
spective review of a large national database that may con-
tain selection bias not unveiled by the current analysis (21, 
22). Selection bias exists in clinical practice and surgeons 
tend to schedule patient with larger tumor for earlier OR 
dates if  possible. Second, the diagnosis of RCC is made with 
cross-sectional imaging unlike bladder and prostate cancers, 
which are diagnosed with biopsy and have a definitive diag-
nosis date; the interval between surgery and diagnosis may 
have been less accurate in this regard. In this database, we 
also noticed a portion of patients who had 0 day interval 
between diagnosis and surgery. This likely results from reim-
aging of the patient on the day of the surgery when progres-
sion is suspected, or results from the patient referral who had 
data missing in the initial encounter and has surgery along 
with outside imaging uploaded on the same day. We excluded 
this portion of patients from the analysis; however, this may 
represent a bias in statistics. Lastly, although the analysis is 
adjusted for confounding factors, this database provides OS 
not ideal for outcome analysis. CSS along with recurrence 
data would provide more directed analysis. The future efforts 
must be directed to investigate the impact of delayed surgery 
in a prospective manner.
Conclusion
In the current study, we used the NCDB and found that the 
vast majority of pT3 patients underwent radical or partial 
nephrectomy within 10 weeks. Delaying definitive surgery 
for more than 10 weeks is associated with decreased 5-year 
OS but not with an increased risk of 30- or 90-day mortality. 
SWT > 10 weeks is associated with tumor upstaging. Addi-
tionally, we found that female patients, African-American or 
Spanish origin patients, treatment in academic or integrated 
network cancer center, lack of insurance, median house-
hold income of less than $38,000, and the Charlson–Deyo 
score of ≥1 are more likely to have delayed definitive surgery. 
 Surgery scheduling is a complex issue and this study adds to 
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